CMP
BMGL

Coston McIsaac & Partners’s Basel Medical BMGL Stock Holding History

Coston McIsaac & Partners’s Portfolio BMGL Stock Details BMGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
4
– – ﹤0.01% 933
2025
Q4 		$0 Hold
4
– – ﹤0.01% 933
2025
Q3 		$0 Buy
+4
New +$100 ﹤0.01% 875

Other funds holding BMGL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Coston McIsaac & Partners's BMGL Position: Q1 2026 in Review

Coston McIsaac & Partners held its Basel Medical (BMGL) position steady in Q1 2026 at 4 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #933.

Coston McIsaac & Partners first reported a position in BMGL in Q3 2025 and has held it in 3 quarters since. 4 funds tracked by Wall St. Rank hold BMGL as of Q1 2026.

  • Coston McIsaac & Partners held 4 shares of Basel Medical worth $0 as of Q1 2026.
  • Coston McIsaac & Partners left its Basel Medical share count unchanged in Q1 2026.
  • Basel Medical made up ﹤0.01% of Coston McIsaac & Partners's portfolio in Q1 2026, its #933 holding.
  • Coston McIsaac & Partners first reported a position in Basel Medical in Q3 2025 and has held it in 3 quarters since.
  • 4 funds tracked by Wall St. Rank held Basel Medical as of Q1 2026.

Based on Coston McIsaac & Partners's 13F filing for Q1 2026, filed 22 Apr 2026.